InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias
SAN FRANCISCO, InCarda
Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company
pioneering a novel approach of treating cardiovascular conditions by delivering
medications via the inhalation route, today announced that it has initiated a Phase
1 clinical trial for its lead product intended to treat recent onset atrial
fibrillation (AF). The single-center trial will evaluate the safety and
tolerability of inhaled flecainide in a randomized, double-blind,
placebo-controlled design consisting of single ascending doses of inhaled
active solution, or inhaled placebo solution, in multiple cohorts of healthy
volunteers. This study is being conducted at CMAX, a division of IDT Australia.
"This is an important step in advancing InCarda's lead product into clinical development," stated Narsi Rangachari, co-founder and chief operating officer of InCarda Therapeutics. "With its novel delivery approach, InCarda is uniquely positioned to develop this rapid-onset treatment for patients with paroxysmal AF."
"The initiation of this trial in Australia represents a key milestone for InCarda," stated Grace E. Colon, Ph.D., chief executive officer and president of InCarda. "Last October we put in place a subsidiary in Australia to allow us to take advantage of leading investigators, medical centers and infrastructure in this important region of medical research, and we also benefit from substantial subsidies that we are applying to our clinical development activities."
Source: InCarda Therapeutics
Comments